18193062. CANCER TREATMENT COMBINATIONS simplified abstract (The Regents of the University of California)
Contents
- 1 CANCER TREATMENT COMBINATIONS
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 CANCER TREATMENT COMBINATIONS - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 How do BTK and ROR-1 antagonists specifically target cancer cells?
- 1.11 What are the potential side effects of combining BTK and ROR-1 antagonists in cancer treatment?
- 1.12 Original Abstract Submitted
CANCER TREATMENT COMBINATIONS
Organization Name
The Regents of the University of California
Inventor(s)
Thomas J. Kipps of San Diego CA (US)
Liguang Chen of San Diego CA (US)
CANCER TREATMENT COMBINATIONS - A simplified explanation of the abstract
This abstract first appeared for US patent application 18193062 titled 'CANCER TREATMENT COMBINATIONS
Simplified Explanation
The abstract describes a patent application for compositions and methods for treating cancer by administering a Bruton's tyrosine kinase (BTK) antagonist and a ROR-1 antagonist to a subject in need. The pharmaceutical compositions include a BTK antagonist, ROR-1 antagonist, and a pharmaceutically acceptable excipient, with specific examples being ibrutinib as the BTK antagonist and cirmtuzumab as the ROR-1 antagonist.
- BTK antagonist (e.g., ibrutinib) and ROR-1 antagonist (e.g., cirmtuzumab) are administered to treat cancer.
- Pharmaceutical compositions include BTK antagonist, ROR-1 antagonist, and excipient for cancer treatment.
Potential Applications
The technology can be applied in the treatment of various types of cancer where BTK and ROR-1 play a role in the progression of the disease.
Problems Solved
This technology addresses the challenge of developing effective treatments for cancer by targeting specific molecular pathways involved in cancer growth and spread.
Benefits
The use of BTK and ROR-1 antagonists in combination can potentially enhance the efficacy of cancer treatment and improve patient outcomes.
Potential Commercial Applications
This technology has potential applications in the pharmaceutical industry for the development of new cancer therapies targeting BTK and ROR-1.
Possible Prior Art
Prior art may include patents or research studies related to the use of BTK or ROR-1 antagonists in cancer treatment, as well as combination therapies targeting multiple pathways in cancer cells.
Unanswered Questions
How do BTK and ROR-1 antagonists specifically target cancer cells?
BTK and ROR-1 antagonists are known to inhibit signaling pathways that promote cancer cell survival and proliferation, but the exact mechanisms of action in cancer cells may require further research.
What are the potential side effects of combining BTK and ROR-1 antagonists in cancer treatment?
While individual BTK and ROR-1 antagonists may have known side effects, the combination therapy could potentially lead to new or exacerbated side effects that need to be carefully monitored and studied in clinical trials.
Original Abstract Submitted
There are provided, inter alia, compositions and methods for treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a Bruton's tyrosine kinase (BTK) antagonist and a ROR-1 antagonist. Further provided are pharmaceutical compositions including a BTK antagonist, ROR-1 antagonist and a pharmaceutically acceptable excipient. In embodiments, the BTK antagonist is ibrutinib and the ROR-1 antagonist is cirmtuzumab.
